
    
      SEVICONTROL-2:

      Efficacy and Safety of a sequential therapy change from Candesartan 32 mg to the fixed
      combination of olmesartan 40 mg/amlodipine 10 mg in patients with poorly controlled moderate
      hypertension - an open phase IV trial
    
  